British pharmacists are struggling to get their hands on certain medicines for cancer, epilepsy, diabetes and menopause as drug supply issues intensify in the country.

UK SCIENTISTS have been told they can no longer take part in meetings organised by a key European infectious diseases agency due to Brexit tensions, it has emerged. / “This is a recognition that Brexit has consequences, and the form of Brexit the UK has chosen has more severe consequences than were necessary."

As Prime Minister Boris Johnson prepares to depart Downing Street, tossed from office by his own party, his legacy — the opening lines of his eventual obituary — will call him the man who “got Brexit done.” / So how is that going? What can be said about the post-Brexit Britain that Johnson is leaving behind?

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

The UK’s medicines and devices regulator will stop work that “does not add value” and lose over 100 full time equivalent staff posts as part of its post-Brexit cost cutting drive, a leaked consultation document seen by The BMJ shows. / But experts warned that plans to streamline regulation to speed up the development and approval of new drugs for patients’ benefit carried potential safety risks.

Crashing out without a deal could contribute to an additional 12,400 cardiovascular deaths between 2021 and 2030, according to the research published in the journal BMJ Open on Monday.